Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Marinus Pharmaceuticals, Inc. - Common Stock (NQ:MRNS)

0.5500 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Marinus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Nervous Markets Rebound As Ukraine Tensions Fade
U.S. President Joe Biden said Russia had started to invade Ukraine and announced steps targeting Russia’s sale of sovereign debt abroad, its elites and a pair of banks. 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Revelation Biosciences (NASDAQ:REVB) stock increased by 29.9% to $2.0 during Wednesday's pre-market session. The market value of their outstanding shares is at... 
Via Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
Marinus Pharma Delays Status Epilepticus, IV Ganaxolone Clinical Trials Into 2023
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) expects data from the RAISE Phase 3 trial of ganaxolone in refractory status epilepticus in 2H of 2023. Earlier data from the trial... 
Via Benzinga
23 Stocks Moving in Wednesday's Pre-Market Session
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) rose 64.9% to $2.54 in pre-market trading after gaining around 5% on Tuesday. Roth Capital recently initiated coverage on the... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Revelation Biosciences (NASDAQ:REVB 
Via Benzinga
Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update
From Marinus Pharmaceuticals
Via Business Wire
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
Via AB Newswire
Topics Bonds Stocks
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright Bioconnect Conference
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Nine Presentations and Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
From Marinus Pharmaceuticals
Via Business Wire
Recap: Marinus Pharmaceuticals Q3 Earnings
Marinus Pharmaceuticals (NASDAQ:MRNS) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the... 
Via Benzinga
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2021 Financial Results on November 9, 2021
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Joins the Loulou Foundation in Collaboration on CANDID, a Comprehensive Observational Study in CDKL5 Deficiency Disorder
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Provides Strategic Update at Virtual R&D Event
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Virtual R&D Event on October 5, 2021
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder
From Marinus Pharmaceuticals, Inc.
Via Business Wire
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
From Marinus Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers PharmaCyte Biotech (NASDAQ:PMCB) shares rose 119.0% to $7.49 during Wednesday's regular session. Trading volume for PharmaCyte Biotech's stock is 144.3... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.